LV10179B - Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them - Google Patents

Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them Download PDF

Info

Publication number
LV10179B
LV10179B LVP-93-1379A LV931379A LV10179B LV 10179 B LV10179 B LV 10179B LV 931379 A LV931379 A LV 931379A LV 10179 B LV10179 B LV 10179B
Authority
LV
Latvia
Prior art keywords
melphalan
hydrochloride
component
citrate
solvent
Prior art date
Application number
LVP-93-1379A
Other languages
English (en)
Other versions
LV10179A (lv
Inventor
Poole Stephen William
Stanley Timothy Paul
Divall Geoffrey
Packham Terence William
Knight Joseph
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LV10179A publication Critical patent/LV10179A/lv
Publication of LV10179B publication Critical patent/LV10179B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

  1. LV 10179 Patentformulas punkti r 1.Injicējams, melfalana sastāvs, kurā melfalans satur divas atsevišķas komponentes a) liofilizētu melfalana hidrohlorīdu, un b) šķīdinātāju-atšķaidītāju, kurš satur citrātu, propilēngli-kolu, ūdeni un etanolu.
  2. 2. Sastāvs saskaņā ar l.p., kur komponente (a) ietver nehidroksilētu matricu veidojošo līdzekli.
  3. 3. Sastāvs saskaņā ar 2.p., kur nehidroksilētais matricu veidojošais līdzeklis ir polivinilpirolidons.
  4. 4. Sastāvs saskaņā ar jebkuru no l.-3.p., kur' citrāts ir sārmmetāla citrāts.
  5. 5. Injicējama melfalana sastāva izgatavošanas paņēmiens, kurā ir divas atsevišķas komponentes: a) liofilizēts melfalana hidrohlorīds un b) šķīdinātājs-atšķaidītājs, kurš satur citrātu, propilēngli-kolu, ūdeni un etanolu.
  6. 6. Būtībā tīra melfalana hidrohlorīda izgatavošanas paņēmiens, kurš ietver melfalaria-un hidrogenhlorīda maisījuma karsēšanu C_ .alkanolā līdz 5 minūtēm un dzesēšanu, lai veicinātu mel- 2-4 1 falana hidrohlorīda kristalizāciju.
LVP-93-1379A 1987-11-19 1993-12-28 Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them LV10179B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878727157A GB8727157D0 (en) 1987-11-19 1987-11-19 Pharmaceutical formulations
EP88310805A EP0317281B1 (en) 1987-11-19 1988-11-16 Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them

Publications (2)

Publication Number Publication Date
LV10179A LV10179A (lv) 1994-10-20
LV10179B true LV10179B (en) 1995-06-20

Family

ID=10627252

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1379A LV10179B (en) 1987-11-19 1993-12-28 Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them

Country Status (22)

Country Link
US (1) US4997651A (lv)
EP (1) EP0317281B1 (lv)
JP (1) JP2693191B2 (lv)
KR (1) KR970002607B1 (lv)
AT (1) ATE83922T1 (lv)
AU (1) AU619781B2 (lv)
CA (1) CA1341114C (lv)
DE (1) DE3877151T2 (lv)
DK (1) DK172794B1 (lv)
ES (1) ES2052745T3 (lv)
FI (2) FI90204C (lv)
GB (1) GB8727157D0 (lv)
GR (1) GR3007287T3 (lv)
HK (1) HK108994A (lv)
HU (3) HU203197B (lv)
IE (1) IE63996B1 (lv)
IL (1) IL88419A (lv)
LV (1) LV10179B (lv)
NZ (2) NZ227004A (lv)
PT (1) PT89028B (lv)
SG (1) SG73894G (lv)
ZA (1) ZA888674B (lv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407672A (en) * 1993-04-08 1995-04-18 Cornell Research Foundation, Inc. Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase
US5695751A (en) * 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
JP2007503475A (ja) 2003-08-26 2007-02-22 リサーチ ディベロップメント ファウンデーション 破骨細胞形成阻害剤およびその使用方法
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
PL3494960T3 (pl) 2008-03-27 2021-05-17 Helsinn Healthcare Sa Stabilizowane kompozycje środków alkilujących i sposoby ich zastosowania
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
PL2434886T3 (pl) * 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
US8921596B2 (en) * 2010-11-04 2014-12-30 Emcure Pharmaceuticals, Ltd. Process for the preparation of melphalan hydrochloride
RS56462B1 (sr) 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
AU2013335359B2 (en) 2012-10-26 2016-07-21 Oncopeptides Innovation Ab Lyophilized preparations of melphalan flufenamide
EP2970102B1 (en) 2013-03-11 2019-05-08 Biophore India Pharmaceuticals Pvt. Ltd. An improved process for the synthesis of melphalan and the hydrochloride salt
ITMI20130896A1 (it) 2013-05-31 2014-12-01 Farmabios Spa Processo di purificazione di melphalan
CA2978040A1 (en) * 2015-03-06 2016-09-15 Leadiant Biosciences S.A. Roneparstat combined therapy of multiple myeloma
WO2017002030A1 (en) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Stable liquid formulations of melphalan
JP7464995B2 (ja) * 2018-03-29 2024-04-10 プロジェクト ファーマシューティクス ゲーエムベーハー 液体薬学的製剤
US10682326B1 (en) 2019-06-03 2020-06-16 Shilpa Medicare Limited Stable melphalan liquid injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
DE1292660B (de) * 1963-04-24 1969-04-17 Ural Polytechnitscheskij I Im Verfahren zur Herstellung von p-(Bis-ª‰-chloraethyl-amino)-phenylalanin-hydrochlorid
US4029778A (en) * 1969-01-23 1977-06-14 Aktiebolaget Leo Cortical steroid nitrogen mustard compositions and treatment therewith
RO57195A2 (lv) * 1970-11-30 1974-09-01
FR2285855A1 (fr) * 1974-09-25 1976-04-23 Kohjin Co Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
JPS62192357A (ja) * 1986-02-19 1987-08-22 Kureha Chem Ind Co Ltd Ｎ−フタロイル−ｐ−ニトロ−Ｌ−フエニルアラニンの製造方法

Also Published As

Publication number Publication date
AU2574888A (en) 1989-05-25
SG73894G (en) 1994-11-25
ZA888674B (en) 1990-07-25
IE63996B1 (en) 1995-06-28
FI885358A (fi) 1989-05-20
DE3877151D1 (de) 1993-02-11
HU9100335D0 (en) 1991-08-28
IL88419A0 (en) 1989-06-30
US4997651A (en) 1991-03-05
FI924668A0 (fi) 1992-10-15
FI90204B (fi) 1993-09-30
AU619781B2 (en) 1992-02-06
HU206671B (en) 1992-12-28
LV10179A (lv) 1994-10-20
CA1341114C (en) 2000-10-10
PT89028A (pt) 1988-12-01
JPH01153628A (ja) 1989-06-15
JP2693191B2 (ja) 1997-12-24
EP0317281A3 (en) 1989-08-09
ATE83922T1 (de) 1993-01-15
HUT48198A (en) 1989-05-29
DK172794B1 (da) 1999-07-19
NZ227004A (en) 1992-11-25
DK646688D0 (da) 1988-11-18
KR890007729A (ko) 1989-07-05
HU203197B (en) 1991-06-28
DE3877151T2 (de) 1993-07-15
PT89028B (pt) 1993-02-26
IL88419A (en) 1993-03-15
IE883447L (en) 1989-05-19
GB8727157D0 (en) 1987-12-23
HK108994A (en) 1994-10-14
EP0317281A2 (en) 1989-05-24
DK646688A (da) 1989-05-20
FI102275B (fi) 1998-11-13
HU910336D0 (en) 1991-08-28
EP0317281B1 (en) 1992-12-30
HU207286B (en) 1993-03-29
FI90204C (fi) 1994-01-10
FI924668A (fi) 1992-10-15
NZ239867A (en) 1992-11-25
ES2052745T3 (es) 1994-07-16
KR970002607B1 (ko) 1997-03-06
FI102275B1 (fi) 1998-11-13
FI885358A0 (fi) 1988-11-18
GR3007287T3 (lv) 1993-07-30

Similar Documents

Publication Publication Date Title
US4997651A (en) Pharmaceutical formulations
JP4192114B2 (ja) 環式付着阻害剤
JP2928047B2 (ja) 安定なポルフィマーナトリウム組成物およびその製造方法
CN103209966B (zh) 6-氟-3-羟基-2-吡嗪甲酰胺的钠盐
EP0306312A1 (en) Lyophilized pharmaceutical composition of neocarzinostatin derivative
EP0067666B1 (en) Salts of antimicrobial naphthyridine and quinoline compounds and their production
JPS60188317A (ja) 抗健忘症剤
CA2849456A1 (en) Methods for treatment of diseases
JP2919867B2 (ja) 抗腫瘍剤
US4772589A (en) Etoposide solution in NMP
HU199289B (en) Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
PH26521A (en) Pharmaceutical formulation
US4322424A (en) Crystalline glucoconate salt of m-AMSA and compositions containing same
KR920006911B1 (ko) 안정한 피록시캄 주사액 조성물 및 그의 제조방법
HU210876A9 (en) Arginine derivatives
HU183357B (en) Process for preparing pharmaceutically acceptable 4'-/9-acridinyl-amino/-methansulphone-m-anizidide salts
JPS6165819A (ja) 有機ゲルマニウム化合物を含有する薬剤組成物
CN1034132A (zh) 含哌啶基环戊基庚烯酸衍生物的水溶液配方
US4626541A (en) Water soluble salt composition of m-AMSA
US4946689A (en) Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin
JPH08502526A (ja) パラ−アミノベンゼンスルファニルアミドの物理的に安定した結晶性α−変態の調製方法
RU2116081C1 (ru) Циклические ингибиторы адгезии
JPS5813556A (ja) 新規な光学活性ジペプチド
JPH03500781A (ja) 結晶（５ｒ，６ｓ）‐２‐カルバモイルオキシメチル‐６‐［（１ｒ）‐ヒドロキシエチル］‐２‐ペネム‐カルボン酸及びその医薬処方物
KR970008483B1 (ko) 신규한 n-4-살리실아미드-2-아미노-6-피페리디노피리미딘 3-옥사이드, 그의 제조방법 및 그를 함유하는 양모제 조성물